Resilience of small intestinal beneficial bacteria to the toxicity of soybean oil fatty acids.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29580380.
- Also identified by DOI 10.7554/eLife.32581 and PMC identifier 5902164.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Over the past century, soybean oil (SBO) consumption in the United States increased dramatically. The main SBO fatty acid, linoleic acid (18:2), inhibits in vitro the growth of lactobacilli, beneficial members of the small intestinal microbiota. Human-associated lactobacilli have declined in prevalence in Western microbiomes, but how dietary changes may have impacted their ecology is unclear. Here, we compared the in vitro and in vivo effects of 18:2 on <i>Lactobacillus reuteri</i> and <i>L. johnsonii</i>. Directed evolution in vitro in both species led to strong 18:2 resistance with mutations in genes for lipid biosynthesis, acid stress, and the cell membrane or wall. Small-intestinal <i>Lactobacillus</i> populations in mice were unaffected by chronic and acute 18:2 exposure, yet harbored both 18:2- sensitive and resistant strains. This work shows that extant small intestinal lactobacilli are protected from toxic dietary components via the gut environment as well as their own capacity to evolve resistance.
Medical subject headings
- Gastrointestinal Microbiome
- Intestine, Small
- Lactobacillus johnsonii
- Limosilactobacillus reuteri
- Linoleic Acid
- Soybean Oil